Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of BTG2 and promotes apoptosis, inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 21/February/2017, 11.16 pm

Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of BTG2 and promotes apoptosis, inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 21/February/2017, 11.16 pm

Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of BTG2 and promotes apoptosis, inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 21/February/2017, 11.16 pm 150 150 Dr Boomi's Genom-2-Discovery Center

Research findings to Therapeutic opportunity: 

price-5

The study presented here suggests that (6)-gingerol (6G), by increasing the expression of its target genes, it may increase the expression of BTG2. Thereby, it may promote apoptosis, inhibit migration, invasion and metastasis of cancer cells. Thus, pharmacological formulations encompassing “(6)-gingerol (6G) or its analogues” may be used to inhibit the progression of invasive tumors.

Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Undisclosed information: How (6)-gingerol (6G) increases the expression of metastasis suppressor BTG2

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

References: 

Citation: Boominathan, L., Natural product-based therapy for Metastatic cancers: (6)-gingerol (6G), one of the main components of Ginger, increases the expression of BTG2 and promotes apoptosis, inhibits migration, invasion and metastasis of cancer cells via down regulation of its target gene, 21/February/2017, 11.16 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Share
MiRNA-based therapy for Metastatic human tumors: MiR-382 decreases the expression of c-Src protein, inhibits the expression of a number of enzymes in glycolytic cycle, and suppresses proliferation, migration, invasion, tumorigenesis and metastasis via up regulation of its target gene, 21/February/2017, 11.08 pm
Small molecule-based PD-1 pathway blockade for Human cancer therapy: Tumor suppressor Menin (MEN1), responsible for multiple endocrine neoplasia type 1 syndrome, decreases the activity of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 22/February/2017, 9.33 pm
Start Typing